Who
Paul J. Diaz
Director
Company insider
Files Form 4 as: Director, Centene; President and CEO, Myriad Genetics; Director, DaVita; CEO, Kindred Healthcare; Director, PharMerica.
In numbers
- Trades disclosed
- 611
- Buys
- 1
- Sells
- 32
- Bought
- $627K
- Sold
- $23.4M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 23 Feb 2006
- Last trade
- 28 Jul 2026
- Last filed
- 28 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 28 Jul 2026 | CNC CenteneManaged Care & Insurers | SEC FORM 4 Code A | —2,771 at $0.00 | filing |
| 28 Jul 2026filed 28 Jul 2026 | CNC CenteneManaged Care & Insurers | SEC FORM 4 Code A | —2,771 at $0.00 | filing |
| 24 Mar 2025filed 25 Mar 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $183K18,312 at $9.98 | filing |
| 24 Mar 2025filed 25 Mar 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $268K26,827 at $9.98 | filing |
| 22 Mar 2025filed 25 Mar 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $199K19,859 at $10.01 | filing |
| 22 Mar 2025filed 25 Mar 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $527K52,682 at $10.01 | filing |
| 15 Mar 2025filed 17 Mar 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $303K30,118 at $10.07 | filing |
| 14 Mar 2025filed 17 Mar 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $378K37,564 at $10.07 | filing |
| 7 Feb 2025filed 4 Mar 2025 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code A | —114,828 at $0.00 | filing |
| 11 Oct 2024filed 11 Oct 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Sold | $344K15,000 at $22.93 | filing |
| 11 Sep 2024filed 12 Sep 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Sold | $401K15,000 at $26.72 | filing |
| 13 Aug 2024filed 14 Aug 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $643K22,808 at $28.18 | filing |
| 13 Aug 2024filed 14 Aug 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $1.4M50,980 at $28.18 | filing |
| 15 May 2024filed 15 May 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Sold | $1.9M75,000 at $25.07 | filing |
| 14 May 2024filed 15 May 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Sold | $2.4M95,000 at $25.21 | filing |
| 13 May 2024filed 15 May 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Sold | $1.5M57,844 at $25.13 | filing |
| 24 Mar 2024filed 25 Mar 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $413K18,589 at $22.24 | filing |
| 24 Mar 2024filed 25 Mar 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $606K27,233 at $22.24 | filing |
| 22 Mar 2024filed 25 Mar 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $449K20,202 at $22.24 | filing |
| 15 Mar 2024filed 18 Mar 2024 | MYGN Myriad GeneticsDiagnostics & Labs | SEC FORM 4 Code F | $648K30,610 at $21.16 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Myriad Genetics (NASDAQ:MYGN) Upgraded at Piper SandlerMYGN · themarketsdaily.com · 23 Oct 2026Myriad Genetics Reports New MRD Detection Data In Colorectal And Pancreatic CancersMYGN · rttnews.com · 22 Oct 2026DaVita Ransomware Settlement Opens Claims Under $15 Million CapDVA · econotimes.com · 21 Oct 2026Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)MYGN · tickerreport.com · 20 Oct 2026
0 headlines in the last 90 days name Paul J. Diaz; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.